SCHEMBL15440463

SCHEMBL15440463

CCOC(=O)c1ccc(O)c(NC(=O)OC(C)(C)C)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.45
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA7 P43166 4/20 0.45
CA9 Q16790 4/20 0.45
CA14 Q9ULX7 4/20 0.45
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
KMT2A Q03164 2/20 0.39
ATR Q13535 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
EGFR P00533 1/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 2/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15553316 0.82 SMN1; SMN2 (0.48) CA12CA1CA2CA7CA9
SCHEMBL15440462 0.79 ATR (0.56) CA12CA1CA2CA7CA9
SCHEMBL15440643 0.79 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL15440468 0.79 LMNA (0.49) KMT2ALMNAMAPK1SMN1; SMN2POLB
SCHEMBL4681713 0.76 RAB9A (0.59) CA12CA1CA2CA7CA9
SCHEMBL15440648 0.76 ALDH1A1 (0.42) CA12CA1CA2CA7CA9
SCHEMBL26745357 0.73 CYP1A2 (0.54) CA12CA1CA2CA7CA9
SCHEMBL5786669 0.72 ATR (0.44) CA12CA1CA2CA7CA9
SCHEMBL8329109 0.71 HTT (0.40) CRHBPCRHR2KMT2ALMNASMN1; SMN2
SCHEMBL8075154 0.71 CA12 (0.56) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2877462-B1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2019-09-04 EP claimed
EP-2877462-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS Celgene Corporation (US) 2015-06-03 EP claimed
WO-2014018866-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 WO claimed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 US claimed
EP-2877462-B1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2019-09-04 EP disclosed
US-9133161-B2 Processes for preparing isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2015-09-15 US disclosed
EP-2877462-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS Celgene Corporation (US) 2015-06-03 EP disclosed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 US disclosed
WO-2014018866-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS UGT1A1, CYP3A5, CYP3A7 CA12 4595/4885CA1 3494/4885CA2 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.